GENKYOTEX SUISSE SA has a total of 35 patent applications. It increased the IP activity by 400.0%. Its first patent ever was published in 2008. It filed its patents most often in Australia, EPO (European Patent Office) and Canada. Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and environmental technology are ATOPIX THERAPEUTICS LTD, INTRA CELLULAR THERAPIES INC and POXEL SAS.
# | Country | Total Patents | |
---|---|---|---|
#1 | Australia | 8 | |
#2 | EPO (European Patent Office) | 7 | |
#3 | Canada | 3 | |
#4 | Israel | 3 | |
#5 | United States | 3 | |
#6 | Brazil | 2 | |
#7 | China | 2 | |
#8 | Republic of Korea | 2 | |
#9 | WIPO (World Intellectual Property Organization) | 2 | |
#10 | Hungary | 1 | |
#11 | Montenegro | 1 | |
#12 | Mexico | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry | |
#3 | Environmental technology | |
#4 | Measurement |
# | Name | Total Patents |
---|---|---|
#1 | Page Patrick | 12 |
#2 | Gaggini Francesca | 11 |
#3 | Sharpe Andrew | 10 |
#4 | Hodges Alastair | 10 |
#5 | Machin Peter | 10 |
#6 | Heitz Freddy | 10 |
#7 | Lock Christopher James | 7 |
#8 | Ellard John M | 7 |
#9 | Thomas Gareth | 7 |
#10 | Allen Vivienne | 7 |
Publication | Filing date | Title |
---|---|---|
EP3628669A1 | Novel compounds as nadph oxidase inhibitors | |
EP3479843A1 | Use of nox inhibitors for treatment of cancer | |
AU2009298004A1 | Pyrazolo Pyridine Compounds as NADPH Oxidase Inhibitors | |
AU2009298006A1 | Pyrazolo pyridine derivatives as NADPH Oxidase inhibitors | |
AU2009298007A1 | Pyrazolo pyridine derivatives as NADPH Oxidase inhibitors |